AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics
AcelRx Pharmaceuticals, Inc. (ACRX)
Today's Latest Price: $1.55 USD
0.06 (-3.73%)
Updated Feb 21 12:00am
Add ACRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ACRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for ACRX is -0.09 -- better than just 6.35% of US stocks.
- ACRX's price/sales ratio is 65.25; that's higher than the P/S ratio of 96.95% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -9.02 for Acelrx Pharmaceuticals Inc; that's greater than it is for only 1.74% of US stocks.
- If you're looking for stocks that are quantitatively similar to Acelrx Pharmaceuticals Inc, a group of peers worth examining would be BIOL, IRIX, ELGX, PMD, and AXGN.
- ACRX's SEC filings can be seen here. And to visit Acelrx Pharmaceuticals Inc's official web site, go to www.acelrx.com.
ACRX Daily Price Range
ACRX 52-Week Price Range
ACRX Stock Price Chart More Charts
ACRX Price/Volume Stats
| Current price | $1.55 | 52-week high | $4.09 |
| Prev. close | $1.61 | 52-week low | $1.48 |
| Day low | $1.54 | Volume | 862,500 |
| Day high | $1.63 | Avg. volume | 704,343 |
| 50-day MA | $1.92 | Dividend yield | N/A |
| 200-day MA | $2.24 | Market Cap | 123.34M |
AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.
Top Stories View All
Best & Worst Performing Stock Industries for February 21, 2020
Best & Worst Performing Small Cap Stocks for February 21, 2020
Best & Worst Performing Mid Cap Stocks for February 21, 2020
Best & Worst Performing Large Cap Stocks for February 21, 2020
Best & Worst Performing Mega Cap Stocks for February 21, 2020
View All Top Stories
Loading social stream, please wait...